Antiendotoxin Monoclonal Antibodies in Sepsis
- First Online:
- 15 Downloads
Gram-negative bacteria release lipopolysaccharide (endotoxin) that causes sepsis and septic shock. Monoclonal antibodies against endotoxins have been proposed as a treatment of sepsis. One such antibody, nebacumab (HA-1A), was released onto the market in some European countries and its approval in the USA was recommended.
However, doubts raised by the lack of reproducible preclinical data, and by an independent reanalysis of the results of the first clinical trial, led to a further clinical trial. This second trial revealed an increase in mortality in nebacumabtreated patients. The trial was stopped and the drug withdrawn from the market.
To avoid such disappointments, the marketing of new biotechnology products should be based on critical scientific analysis, free from commercial pressures, of thorough, reproducible and consistent preclinical and clinical studies.
Unable to display preview. Download preview PDF.
- 1.Increase in National Hospital Discharge Survey rates for septicemia — United States, 1979–1987 [editorial]. Morb Mortal Wkly Rep 1990; 39: 31–4Google Scholar
- 5.Baumgartner JD, Eggimann P, Glauser MP. Management of septic shock: new approaches. In: Remington JS, Swartz MN, editors. Current clinical topics in infectious diseases, vol. 12. Cambridge: Blackwell Scientific, 1992: 165–87Google Scholar
- 8.McCutchan JA, Wolf JL, Ziegler EJ, et al. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infection in patients with prolonged neutropenia. Schweiz Med Wochenschr 1983; 113Suppl. 14: 40–5Google Scholar
- 15.Baumgartner JD, Heumann D, Glauser MP. The HA-1A monoclonal antibody for gram-negative sepsis [letter]. N Engl J Med 1991; 325: 281–2Google Scholar
- 16.Baumgartner JD, Heumann D, Gerain J, et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor α and interleukin 6: comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med 1990; 171: 889–96PubMedCrossRefGoogle Scholar
- 20.Wenzel R, Bone R, Fein A, et al. Results of a second double-blind, randomized, controlled trial of antiendotoxin antibody E5 in gram-negative sepsis [extended abstract]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991 Sep 29–Oct 2; Chicago. Washington DC: American Society for Microbiology, 1991: 294Google Scholar
- 22.Winslow R. Effectiveness of new drug against septic infections is questioned by agency. Wall Street Journal 1992 Apr 16; B5Google Scholar
- 23.Fisher LM. Investors punish Centocor for more bad news. New York Times 1993 Jan 19; D1Google Scholar
- 25.Tanio CP, Feldman HI. The HA-1A monoclonal antibody for gram-negative sepsis [letter]. N Engl J Med 1991; 325: 280Google Scholar
- 26.Carlet J, Offenstadt G, Chastang C. The HA-1A monoclonal antibody for gram-negative sepsis [letter]. N Engl J Med 1991; 325: 280Google Scholar
- 27.Schmidt GA. The HA-1A monoclonal antibody for gram-negative sepsis [letter]. N Engl J Med 1991; 325: 280–1Google Scholar
- 28.Peled HB. The HA-1A monoclonal antibody for gram-negative sepsis [letter]. N Engl J Med 1991; 325: 281Google Scholar
- 29.Ziegler EJ, Fisher CJ, Sprung CL. The HA-1A monoclonal antibody for gram-negative sepsis [letter]. N Engl J Med 1991; 325: 282–3Google Scholar
- 31.Di Padova FE, Barclay R, Liehl E, et al. Widely cross-reactive anti-LPS core monoclonal antibodies have LPS neutralizing properties. Abstract CB404. J Cell Biochem 1992; Suppl. 16C–170Google Scholar
- 33.Piercey L. Star-crossed lovers — is biotech bad for science? Biopeople 1993; 4: 20–7Google Scholar
- 34.Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. J Biol Chem 1998; 263: 13479–81Google Scholar
- 36.Marra MN, Snable JL, Scott RW, et al. Bactericidal/permeability-increasing protein: a naturally occurring lipopolysaccharide antagonist. Circ Shock 1991; 34–7Google Scholar